Xenomics’ Diagnostic Test for AML Available to Clinicians
Tool detects all 45 mutations of a gene characterized in 30% to 40% of cases.
Xenomics reports that its first diagnostic test for stratification of patients with acute myeloid leukemia (AML) has been implemented at CLIA approved BRT Laboratories and is available to clinicians.
This test is based on a recent discovery that mutations in a nucleophosmin (NPM1) gene are characteristic of 30% to 40% of the cases of AML. NPM1 is a protein involved in regulation of ribosome biogenesis, cell division, cell death, and other important processes, Xenomics states. The company says that it has developed a diagnostic tool that detects all 45 known mutations of NPM1 in a single reaction.